Rare Pediatric Disease Priority Review Voucher

Capitol Building and Congress
Favicon Fierce Pharma

FDA’s rare pediatric voucher program revived by funding bill

Congress has struggled over the last year to bring back the beloved program, which initially expired at the end of 2024.
Darren Incorvaia Feb 4, 2026 3:12pm
RNA Concept 3D Render

RNA biotech emerges with $52M and clinical rare disease asset

Aug 25, 2025 10:13am
Man hands gold dollar sign to another man
Favicon Fierce Pharma

Bavarian Nordic's $160M PRV price reflects new realities

Jun 18, 2025 11:47am
Money in the hands of businessmen with contract signing

PTC sells priority review voucher from Kebilidi nod for $150M

Nov 27, 2024 8:35am
money funding financing bank

Acadia makes $100M profit from $150M pediatric voucher sale

Nov 6, 2024 9:36am
curtains spotlight show performance

AAV gene therapy biotech unveils with 10 pipeline products

Sep 12, 2024 7:00am